Latest Insider Transactions at Inozyme Pharma, Inc. (INZY)
This section provides a real-time view of insider transactions for Inozyme Pharma, Inc. (INZY). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Inozyme Pharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Inozyme Pharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Sep 30
2024
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+25.88%
|
$6,840
$4.45 P/Share
|
|
Sep 30
2024
|
Douglas A Treco CEO |
BUY
Grant, award, or other acquisition
|
Direct |
1,710
+7.1%
|
$6,840
$4.45 P/Share
|
|
Apr 02
2024
|
Douglas A Treco CEO |
SELL
Open market or private sale
|
Direct |
7,523
-26.69%
|
$45,138
$6.94 P/Share
|
|
Apr 01
2024
|
Douglas A Treco CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+47.0%
|
-
|
|
Mar 28
2024
|
Matthew Winton COO |
BUY
Grant, award, or other acquisition
|
Direct |
3,188
+50.0%
|
$9,564
$3.33 P/Share
|
|
Sep 29
2023
|
Sanjay Subramanian SVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
2,319
+7.09%
|
$6,957
$3.57 P/Share
|
|
Aug 01
2023
|
Pivotal Bio Venture Partners Fund I, L.P. |
BUY
Open market or private purchase
|
Indirect |
833,333
+17.58%
|
$3,333,332
$4.8 P/Share
|
|
Aug 01
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
833,333
+17.58%
|
$3,333,332
$4.8 P/Share
|
|
May 12
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
228,702
+5.88%
|
$1,372,212
$6.25 P/Share
|
|
May 11
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
219,230
+6.0%
|
$1,315,380
$6.48 P/Share
|
|
Mar 31
2023
|
Axel Bolte |
BUY
Grant, award, or other acquisition
|
Direct |
4,806
+1.77%
|
$9,612
$2.21 P/Share
|
|
Mar 31
2023
|
Sanjay Subramanian SVP, CFO |
BUY
Grant, award, or other acquisition
|
Direct |
979
+3.37%
|
$1,958
$2.21 P/Share
|
|
Mar 29
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
344,592
+9.68%
|
$1,378,368
$4.54 P/Share
|
|
Mar 28
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
156,766
+5.18%
|
$627,064
$4.16 P/Share
|
|
Mar 27
2023
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
51,074
+1.85%
|
$153,222
$3.7 P/Share
|
|
Dec 15
2022
|
Henric Bjorn Bjarke SVP, COO |
BUY
Open market or private purchase
|
Direct |
21,500
+16.94%
|
$21,500
$1.39 P/Share
|
|
Sep 30
2022
|
Axel Bolte |
BUY
Grant, award, or other acquisition
|
Direct |
3,315
+1.25%
|
$6,630
$2.28 P/Share
|
|
Sep 30
2022
|
Henric Bjorn Bjarke SVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
3,315
+3.8%
|
$6,630
$2.28 P/Share
|
|
Apr 19
2022
|
Longitude Capital Partners Iii, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
1,355,000
+24.51%
|
$4,065,000
$3.69 P/Share
|
|
Apr 19
2022
|
Sanjay Subramanian SVP, CFO |
BUY
Open market or private purchase
|
Direct |
27,100
+50.0%
|
$81,300
$3.69 P/Share
|
|
Apr 19
2022
|
Robert Lorne Hopfner |
BUY
Open market or private purchase
|
Indirect |
1,070,000
+28.68%
|
$3,210,000
$3.69 P/Share
|
|
Apr 19
2022
|
Axel Bolte |
BUY
Open market or private purchase
|
Direct |
67,750
+20.76%
|
$203,250
$3.69 P/Share
|
|
Apr 19
2022
|
Henric Bjorn Bjarke SVP, COO |
BUY
Open market or private purchase
|
Direct |
27,100
+25.16%
|
$81,300
$3.69 P/Share
|
|
Apr 19
2022
|
Pivotal Bio Venture Partners Fund I, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,070,000
+28.68%
|
$3,210,000
$3.69 P/Share
|
|
Jun 24
2021
|
Axel Bolte |
SELL
Open market or private sale
|
Direct |
66,788
-25.93%
|
-
|
|
Jun 24
2021
|
Axel Bolte |
BUY
Exercise of conversion of derivative security
|
Direct |
66,788
+20.59%
|
$0
$0.98 P/Share
|
|
Jan 28
2021
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
375,000
-14.6%
|
$7,875,000
$21.0 P/Share
|
|
Jul 28
2020
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
375,000
+12.74%
|
$6,000,000
$16.0 P/Share
|
|
Jul 28
2020
|
Novo Holdings > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
2,194,379
+50.0%
|
-
|
|
Jul 28
2020
|
Sanofi > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
81,250
+13.51%
|
$1,300,000
$16.0 P/Share
|
|
Jul 28
2020
|
Sanofi > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
438,875
+50.0%
|
-
|
|
Jul 28
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600,000
+23.04%
|
$9,600,000
$16.0 P/Share
|
|
Jul 28
2020
|
Ra Capital Management, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,403,653
+50.0%
|
-
|
|
Jul 28
2020
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
600,000
+18.88%
|
$9,600,000
$16.0 P/Share
|
|
Jul 28
2020
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
467,884
+50.0%
|
-
|